cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Nuvalent Inc
3 own
3 watching
Current Price
$44.59
$2.09
(4.92%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
939.32M
52-Week High
52-Week High
44.61
52-Week Low
52-Week Low
8.505
Average Volume
Average Volume
0.42M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization939.32M
icon52-Week High44.61
icon52-Week Low8.505
iconAverage Volume0.42M
iconDividend Yield--
iconP/E Ratio--
What does the Nuvalent Inc do?
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase I/II clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Read More
How much money does Nuvalent Inc make?
News & Events about Nuvalent Inc.
PR Newswire
1month ago
Nuvalent Presents New Preclinical Data Supporting Intracranial Activity of NVL-655 at AACR Annual Meeting 2023 Nuvalent Presents New Preclinical Data Supporting Intracranial Activity of NVL-655 at AACR Annual Meeting 2023 PR Newswire CAMBRIDGE, Mass., April 18, 2023 CAMBRIDGE, Mass., April 18, 2023...
PR Newswire
5 months ago
Nuvalent Announces Publication in Cancer Discovery Detailing Design and Characterization of ROS1-selective inhibitor NVL-520 Nuvalent Announces Publication in Cancer Discovery Detailing Design and Characterization of ROS1-selective inhibitor NVL-520 PR Newswire CAMBRIDGE, Mass., Dec. 13, 2022...
PR Newswire
7 months ago
Nuvalent Announces Closing of Upsized Public Offering of Common Stock Nuvalent Announces Closing of Upsized Public Offering of Common Stock PR Newswire CAMBRIDGE, Mass., Nov. 3, 2022 CAMBRIDGE, Mass., Nov. 3, 2022 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical...
PR Newswire
7 months ago
Nuvalent Announces Pricing of Public Offering of Common Stock Nuvalent Announces Pricing of Public Offering of Common Stock PR Newswire CAMBRIDGE, Mass., Oct. 31, 2022 CAMBRIDGE, Mass., Oct. 31, 2022 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused...
PR Newswire
7 months ago
Nuvalent Reports Preliminary Phase 1 Clinical Data from ARROS-1 Trial that Support Best-In-Class Potential of NVL-520 for Patients withROS1-Positive NSCLC Nuvalent Reports Preliminary Phase 1 Clinical Data from ARROS-1 Trial that Support Best-In-Class Potential of NVL-520 for Patients...
Frequently Asked Questions
Frequently Asked Questions
What is Nuvalent Inc share price today?
plus_minus_icon
Can Indians buy Nuvalent Inc shares?
plus_minus_icon
How can I buy Nuvalent Inc shares from India?
plus_minus_icon
Can Fractional shares of Nuvalent Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Nuvalent Inc stocks?
plus_minus_icon
What is today’s traded volume of Nuvalent Inc?
plus_minus_icon
What is today’s market capitalisation of Nuvalent Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Nuvalent Inc?
plus_minus_icon
What percentage is Nuvalent Inc down from its 52-Week High?
plus_minus_icon
What percentage is Nuvalent Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$44.59
$2.09
(4.92%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00